Showing 7471-7480 of 9070 results for "".
- 2023 Medscape Report: Physician Salaries Rise as Gender Gap Narrowshttps://practicaldermatology.com/news/2023-medscape-report-physician-salaries-rise-as-gender-gap-narrows/2461663/Doctor salaries continue to rise as the gender gap narrows, according to the 2023 Medscape Physician Compensation Report. The largest difference for women was seen in primary care, but the disparity also narrowed within specialties, from a 36% difference i
- FDA Clears New Underarm Sweat Control Patchhttps://practicaldermatology.com/news/fda-clears-new-underarm-sweat-control-patch/2461660/The U.S. Food and Drug Administration (FDA) has cleared cleared Brella, the first 3-Minute SweatControl Patch to significantly reduce excessive underarm sweating in adults with primary axillary hyperhidrosis. The Brella SweatControl Patch provide
- Survey: Gen Z and Millennial Men Fall Short on Face Washing, Skin Carehttps://practicaldermatology.com/news/survey-gen-z-and-millennial-men-fall-short-on-face-washing-skin-care/2461656/Many Gen Z and millennial men would rather going on a bad date than take care of their skin, according to a new survey conducted by OnePoll on behalf of CeraVe. In a recent survey of 2,000 men ages 18–26 and 27–42, two in five (42%) revealed they need someone to confront the
- Prior Immunotherapy May Predict Response to PD-1 Checkpoint Blockadehttps://practicaldermatology.com/news/prior-immunotherapy-may-predict-response-to-pd-1-checkpoint-blockade/2461655/Responses to PD-1 checkpoint blockade in patients with advanced melanoma depend on whether or not they had previously received CTLA-4 blockade as well as other factors, new research suggests. Their findings, based on analysis of seven data sets generated over the past decade, which incl
- News You Can Use: BI Receives Permanent J-Code (J1747) for SPEVIGO Injectionhttps://practicaldermatology.com/news/news-you-can-use-bi-receives-permanent-j-code-j1747-for-spevigo-injection/2461649/The U.S. Centers for Medicare & Medicaid Services (CMS) has issued a permanent J-code (J1747) for Boehringer Ingelheim’s SPEVIGO (spesolimab-sbzo) Injection, indicated for the treatment of generalized pustular psoriasis (GPP) flares in adults. The J-code for SPEVIGO became eff
- Millennials, Gen Xers Not Well-Schooled on Skin Cancer Preventionhttps://practicaldermatology.com/news/millennials-gen-xers-not-well-schooled-on-skin-cancer-prevention/2461648/Millennials and Gen Xers are racked with sun regrets, a new survey shows. Just 19% of millennials and Gen Xers wear sunscreen all year, 35% used a tanning bed, and 46% regretted how long they stayed out in the sun when they were younger. This is why
- Mount Sinai Wins $1.3M Grant to Expand Skin Biology Research Training Programhttps://practicaldermatology.com/news/mount-sinai-wins-13m-grant-to-expand-skin-biology-research-training-program/2461643/The Kimberly and Eric J. Waldman Department of Dermatology at the Icahn School of Medicine at Mount Sinai will expand its research training program in skin biology with support from a five-year, $1.3 million T32 grant from the National Institutes of Health (NIH) and the National Institute of Arth
- Treatment Options to Consider for Pregnant Women Living with Eczema and Psoriasishttps://practicaldermatology.com/news/treatment-options-to-consider-for-pregnant-women-living-with-eczema-and-psoriasis/2461639/Psoriasis and eczema affect men and women differently, with women needing to take extra precautions when considering treatments if they’re planning for pregnancy, according to a news release from the American Academy of Dermatology. At the recent American Academy of Dermatology&rs
- HS Update: Studies Suggest TNF, IL-17, and JAK inhibitors May Play a Role in Treating HShttps://practicaldermatology.com/news/hs-update-studies-suggest-tnf-il-17-and-jak-inhibitors-may-play-a-role-in-treating-hs/2461627/Several new potential therapies for hidradenitis suppurativa (HS) are coming down the pike, according to research presented at the 2023 American Academy of Dermatology (AAD) Annual Meeting in New Orleans. Acelyrin, Inc.'s Izokibep led to HiSCR response at 12 weeks, including H
- Take That SKs! DermBiont’s SM-020 Topical Gel Performs Well in Phase 2 Studyhttps://practicaldermatology.com/news/take-that-sks-dermbionts-sm-020-topical-gel-performs-well-in-phase-2-study/2461623/More than 80% of seborrheic keratosis (SK) lesions treated for 14 to 28 days with DermBiont’s SM-020 gel 1.0% had at least a one-point improvement in Physician’s lesion assessment (PLA) score at last visit, according to Phase 2 trial data presented at the